Hubei Jumpcan Pharmaceutical Co., Ltd.

600566

CNE0000018X6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-03-13			5-day change	1st Jan Change
26.53 ^CNY	-0.34%		-4.40%	+0.87%

Feb. 26	Hubei Jumpcan Secures Exclusive China Rights For Eczema Treatment	MT
Feb. 03	Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit	MT

Jumpcan Pharmaceutical Gets Rights for Pumeixitinib Nasal Spray for 100 Million Yuan

Published on 02/02/2026 at 11:09 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Hubei Jumpcan Pharmaceutical Co., Ltd.

Feb. 26	Hubei Jumpcan Secures Exclusive China Rights For Eczema Treatment	MT
Feb. 03	Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit	MT
Feb. 02	Jumpcan Pharmaceutical Gets Rights for Pumeixitinib Nasal Spray for 100 Million Yuan	MT
Jan. 04	Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 24, 2025.	CI
Nov. 24	Hubei Jumpcan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	CI
Nov. 23	Hubei Jumpcan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	CI
25-10-28	Jumpcan Pharmaceutical's Q3 Profit Drops 47%, Revenue Falls 33%	MT
25-10-27	Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-09-17	Jumpcan Pharma Gets Registration Certificate for Lidocaine Cataplasms	MT
25-08-25	Hubei Jumpcan Pharmaceutical's Attributable Profit Slides 46% in H1; Shares Fall 4%	MT
25-08-22	Hubei Jumpcan Pharmaceutical H1 net profit down 45.9% Y/Y	RE
25-08-22	Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-21	Tranche Update on Hubei Jumpcan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 23, 2024.	CI
25-07-21	Cao Fei Completes Partial Tender Offer for Jumpcan Pharmaceutical Shares	MT
25-07-21	Jumpcan Pharmaceutical Gets Registration Certificate for Masiloxavir Tablets	MT

Chart Hubei Jumpcan Pharmaceutical Co., Ltd.

Duration

Period

Chart Hubei Jumpcan Pharmaceutical Co., Ltd.

600566: Dynamic Chart

HUBEI JUMPCAN PHARMACEUTICAL CO., LTD., formerly Hubei Hongcheng General Machinery Co., Ltd., is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The Company mainly distributes its products within domestic markets.

Employees

5,026

Sector

Pharmaceuticals

Calendar

Apr. 24 - Earnings release - Annual 2025

More about the company